| Basics |
Wave Life Sciences Ltd. Ordinary Shares
WAVE Life Sciences Ltd is a preclinical therapeutics developer in Singapore. Its pipeline of drugs is intended to cure rare genetic disorders such as Huntington, duchenne muscular dystrophy (DMD) and inflammatory bowel disease.
|
| IPO Date: |
November 11, 2015 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$1.25B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.47 | 3.32%
|
| Avg Daily Range (30 D): |
$0.27 | 3.64%
|
| Avg Daily Range (90 D): |
$0.23 | 2.95%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.5M |
| Avg Daily Volume (30 D): |
2.77M |
| Avg Daily Volume (90 D): |
2.17M |
| Trade Size |
| Avg Trade Size (Sh.): |
104 |
| Avg Trade Size (Sh.) (30 D): |
107 |
| Avg Trade Size (Sh.) (90 D): |
99 |
| Institutional Trades |
| Total Inst.Trades: |
1,174 |
| Avg Inst. Trade: |
$1.48M |
| Avg Inst. Trade (30 D): |
$1.54M |
| Avg Inst. Trade (90 D): |
$1.62M |
| Avg Inst. Trade Volume: |
.14M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$1.7M |
| Avg Closing Trade (30 D): |
$1.81M |
| Avg Closing Trade (90 D): |
$1.66M |
| Avg Closing Volume: |
180.49K |
|
|
| Financials |
| |
TTM |
Q3 2025 |
Q2 2025 |
|
Basic EPS
|
$-.65
|
$-.32
|
$-.31
|
|
Diluted EPS
|
$-.65
|
$-.32
|
$-.31
|
|
Revenue
|
$ 109.23M
|
$ 7.61M
|
$ 8.7M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$ -121.95M
|
$ -53.85M
|
$ -50.47M
|
|
Operating Income / Loss
|
$ -135.95M
|
$ -56.35M
|
$ -52.76M
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$ -114.65M
|
$ -12.22M
|
$ -34.63M
|
|
PE Ratio
|
|
|
|
|
|
|
